Valuation dashboard for IQVIA Holdings Inc. (IQV) with P/E 32.48, P/B 6.61, EV/EBITDA 16.2 and dividend yield 0.00%. DCF, Graham Number, EPS growth, peer multiples and dividend discount models plus sector comparison against other Healthcare companies.
IQVIA Holdings Inc. is a premier global provider of sophisticated analytical insights, advanced technology solutions, and comprehensive clinical research services, catering to the life sciences industry across the Americas, Europe, Africa, and Asia-Pacific. The company's operations are structured into three key divisions: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
What would it be worth at its usual multiples?
Versus its usual multiples: fairly priced · Current P/E 32.5× · Multiples range: $252.58 · $270.36.
At the decade median (32.9×) $270 (+1 %); at its sector median (30.7×) $253 (-6 %). Implied price from applying the reference multiples to today's earnings (or book value, or FFO) per share. Not a fair value: it is where the stock would trade at its usual multiples.
Analysis Summary
IQVIA Holdings Inc. reported revenue of $16.31B in the most recent fiscal year, growing at a 5-year CAGR of 7.5%. Net income reached $1.36B, with a 37.3% 5-year CAGR.
Trailing-twelve-month margins: gross margin 26.5%, operating margin 13.4%, net margin 8.1%.
At $267.33 (closing price, October 30, 2026), IQV trades at a P/E of 32.48 and an ROE of 21.82%. Market capitalisation stands at $44.1B, placing it among large-cap names.
Balance sheet quality for IQV: debt-to-equity ratio of 2.45, current ratio of 0.83 over the last 12 months. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| P/E Ratio | 32.48 |
| Price / Book | 6.61 |
| EV / EBITDA | 16.2 |
| Dividend Yield | 0.00% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| IQV | IQVIA Holdings Inc. | $44.1B | 32.48 | 6.61 | 21.8% |
| MEDP | Medpace Holdings, Inc. | $18.2B | 36.14 | 31.14 | 99.8% |
| ICLR | ICON Public Limited Company | $16.3B | 36.38 | 1.78 | 4.9% |
| TEM | Tempus AI, Inc. | $13.4B | 27.57 | -40.9% | |
| VEEV | Veeva Systems Inc. | $50.7B | 51.47 | 6.84 | 14.0% |
| CRL | Charles River Laboratories International, Inc. | $17.3B | 6.14 | -7.7% |
Price
| Price | $267.33 (closing price, October 30, 2026) |
| Market Cap | $44.1B |
| Exchange | NYSE |
| Country | US |
Profitability
| Return on Equity | 21.82% |
| Return on Invested Capital | 8.20% |
| Return on Assets | 4.57% |
| Gross Margin | 26.46% |
| Operating Margin | 13.42% |
| Net Margin | 8.05% |
Related companies: MEDP · ICLR · TEM · VEEV · CRL
Explore sector: Healthcare · Medical - Diagnostics & Research
More sections of IQV: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks